Dual Face Apoptotic Machinery: From Initiator of Apoptosis to Guardian of Necroptosis  by Declercq, Wim et al.
Immunity
PreviewsSubsequent GTP hydrolysis and con-
formational changes in MxA presumably
induce stress sufficient to destabilize
bound viral nucleoproteins. Clearly, MxA
needs to function much more flexibly
than dynamins given that it interacts with
a variety of viral targets. Although the
overall structural elements and assembly
properties are closely shared with dyna-
min, the detailed mechanism of action on
its viral targets awaits further analysis of
MxA-nucleoprotein complexes. Toward
this end, the influenza A virus nucleopro-
tein crystal structure has been reported
(Ye et al., 2006), suggesting the possibilityof molecular modeling or even cocrystalli-
zation with MxA in the near future.REFERENCES
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In this issue of Immunity, Bonnet et al. (2011) show that skin-specific ablation of the adaptor protein FADD
sensitizes keratinocytes to RIPK3-dependent necrotic cell death, which leads to severe skin inflammation.The skin is the first line of defense against
environmental insults such as chemical,
physical, and microbial challenges and
protects against water loss. It consists
of an outer squamous epithelium, the
epidermis, and the dermis. The epidermis
mainly contains keratinocytes, which
differentiate in order to produce functional
skin. Defects in the homeostasis between
keratinocyte proliferation and differentia-
tion cause a variety of skin disorders,
including psoriasis, dermatitis, and skin
cancer. Because the epidermis is con-
stantly challenged by antigens and mi-
crobes, it also acts as an immune barrier
producing antimicrobial peptides and
contains different types of inflamma-
somes. To prevent excessive inflamma-
tion, desensitizing mechanisms probably
exist in the epidermal layers of skin
and in theepithelia lining thegut and lungs.In this issue of Immunity, Bonnet et al.
(2011) show that in experimentally unchal-
lenged skin, the apoptotic machinery in
keratinocytes protects the epidermis
against necroptosis and severe inflamma-
tion. Their data suggest that prevention
of necrotic cell death could be exploited
in managing inflammatory skin diseases.
Inappropriate cell death in the epi-
dermis can disrupt the architecture and
integrity of the skin and lead to inflamma-
tion, barrier disruption, blistering, and
excessive water loss. There are twomajor
morphological forms of cell death: apo-
ptosis and necrosis. The major cell death
pathway during homeostasis and dis-
ease, apoptosis, removes unwanted and
harmful cells in an immunologically silent
way. Necrosis has long been considered
an accidental form of cell death caused
by physical or chemical damage. Duringrecent years it has become clear that
certain necrotic cell death pathways are
as controlled and programmed as apo-
ptosis and are therefore called regulated
necrosis or necroptosis (Vandenabeele
et al., 2010). The best-studied ligand
involved in necroptosis induction is
tumor necrosis factor (TNF). Triggering
of its main receptor (TNFR1) results in
formation of multiprotein complexes
that can induce inflammatory signaling,
apoptosis, or necroptosis. The signaling
pathways governing apoptosis and nec-
roptosis interact mutually. The receptor
interacting kinases RIPK1 and RIPK3
decide life and death, but can be inacti-
vated by the apoptotic machinery (FADD,
caspase-8, and FLIPL). Upon TNF
stimulation in the absence of sufficient
caspase-8 activation (e.g., in the pres-
ence of chemical or viral caspase, October 28, 2011 ª2011 Elsevier Inc. 493
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Figure 1. Dual Function of the Apoptosis Machinery as the Initiator of Apoptosis or the
Guardian against Necroptosis
In tissues, caspase-8, FADD, FLIPL, RIPK1, and RIPK3 can form a multiprotein complex called DISC
(death-inducing signaling complex), possibly resembling the ripoptosome. Activation of procaspase-8
within this complex results in cleavage of RIPK1 and RIPK3, rendering the necroptosis-inducing complex
(necrosome) inactive, eventually leading to apoptotic cell death. This anti-necroptosis function of the
apoptosis machinery probably acts as a general mechanism to preserve tissue integrity. In contrast,
absence or insufficient activation of caspase-8 allows RIPK1 association with RIPK3, triggering a signaling
cascade leading to necroptosis. Necroptosis induces inflammation through release of intracellular
DAMPs. Increased cytokine concentrations during inflammation can further amplify necroptosis, thereby
fueling vehement inflammation.
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Previewsinhibitors, low caspase-8 levels, absence
of adaptor FADD), RIPK1 and RIPK3
form the necrosome complex that signals
to necroptosis (Vandenabeele et al.,
2010) (Figure 1). The importance of con-
trolling necroptosis during development
is evident from the embryonic mortality
of Fadd/ or Casp8/ mice, which can
be rescued by ablation of RIPK1 or
RIPK3 (Kaiser et al., 2011; Oberst et al.,
2011; Zhang et al., 2011). Specific abla-
tion of caspase-8 in keratinocytes results
in severe skin inflammation and neonatal
death (Kovalenko et al., 2009; Lee et al.,
2009), which is not observed in full
Casp8/Ripk3/ mice (Kaiser et al.,
2011). This suggested that necroptosis
could be the default pathway in of live
epidermis that needs continuous sup-
pression by the apoptotic machinery to
avoid activation. The RIPK1 ubiquitination
status dictates whether RIPK1 promotes
cell death (apoptosis or necrosis) or sur-
vival. Lysine 63 (K63)-coupled ubiquitin
chains attached to RIPK1 promote the
activation of MAPKs and NF-kB. These
chains can be removed by deubiquiti-
nases such as cylindromatosis (CYLD),
which mediates TNF-induced necropto-
sis (Hitomi et al., 2008). The necroptotic
signaling cascades are being elucidated,494 Immunity 35, October 28, 2011 ª2011 Elbut the contribution of necrotic cell death
to disease is largely unknown.
Bonnet et al. (2011) show that epi-
dermis-specific deletion (E-KO) of Fadd,
like epidermal deletion of Caspase 8,
leads to severe skin inflammation marked
byepidermal hyperplasia, loss of the gran-
ular layer, hyperkeratosis, and immune
cell infiltration in the epidermis and
dermis. At birth, FADDE-KO mice are visu-
ally indistinguishable from control litter-
mates. Three days after birth, they start
to show signs of skin inflammation, which
progressively leads to deathwithin 5 days.
Consequently, the amounts of IL-1b, IL-6,
TNF, and IL-10 are substantially increased
in FADDE-KO skin relative to controls. This
increase in cytokines was associated
with an increase in necrotic cells in the
epidermis, which was followed by signs
of inflammation. These data indicate
that unknown postnatal triggers induce
necroptosis and skin inflammation.
To genetically dissect the mechanism
by which FADDE-KO mice develop ne-
crotic inflammatory skin lesions, Bonnet
et al. (2011) crossed these mice with
different mouse strains deficient in key
regulators of cell death and inflammation.
Because TNF concentrations were upre-
gulated in FADDE-KO mice and TNF issevier Inc.a well known inducer of necroptosis in
cellular models, TNF was the prime sus-
pect. Surprisingly, although development
of skin lesions was delayed in FADDE-KO
Tnf/, FADDE-KO Tnfr1/, or FADDE-KO
CyldD932E (lacking ubiquitin chain hydro-
lase activity) mice, the mice were not
protected. Therefore, additional death-
inducing ligands and receptors and nec-
roptosis-regulating mechanisms could be
involved in the development of skin inflam-
mation in FADDE-KO mice. In contrast,
double-deficient FADDE-KO Ripk3/ mice
showed neither skin inflammation nor
necroptosis. Their IL-1b, IL-6, and TNF
cytokine concentrations were normal,
which shows that induction of these cyto-
kineswassecondary tonecrosis induction.
These data indicate that necrotic death of
keratinocytes is the cause of the severe
skin inflammation in FADDE-KO mice. It is
astonishing that very few necroptotic cells
(2–3 cells per mm tissue in sections) can
ignite extensive inflammation. This sug-
gests that in vivo necrotic cell death might
have been overlooked in many studies
and argues for a rigorous re-evaluation of
pathological tissues.
Necrotic cells spill their intracellular
content, which contains different necrotic
danger-associated molecular patterns
(nDAMPs). DAMPs can trigger inflamma-
tion by activating pattern recognition re-
ceptors (PRRs), including Toll-like
receptors (TLRs), NOD-like sensors, and
RIG-I-like receptors. However, crossing
FADDE-KO mice with mice deficient in
MyD88, amajor signalingmolecule down-
stream of most TLRs, only led to a slight
delay in the appearance of inflammatory
lesions in the progeny. Thus, many
different DAMP-sensing receptors prob-
ably participate in amplifying skin inflam-
mation. Candidate PRRs are RAGE and
Mincle, which respectively recognize
HMGB1 and SAP130, two nuclear pro-
teins released from necrotic cells. RAGE
recognizes small S100 calcium-binding
proteins, which are strongly upregulated
in inflammatory skin diseases such as
psoriasis. Further experimentation will
show the role of these receptors in driving
skin inflammation.
Other studies recently demonstrated
that RIPK1- or RIPK3-dependent necrop-
tosis also accounts for the severe inflam-
matory response in the small intestine
(enteritis) and the colon (colitis) observed
in mice with FADD or caspase-8 deletion
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Previewsin intestinal epithelial cells (IEC-KO)
(Gu¨nther et al., 2011; Welz et al., 2011).
These findings indicate that negative
regulation of necroptosis by components
of the apoptotic machinery is a general
mechanism for restraining necroptosis.
However, necroptosis induction and sub-
sequent inflammation in FADDIEC-KO mice
is regulated differently in the small intes-
tine and the colon. The inflammatory
phenotype of FADDIEC-KO colon can be
rescued by additional ablation of Cyld,
MyD88, or Tnf (only partially in the latter
case) or by treatment with antibiotics,
but this is not so for FADDIEC-KO enteritis
(Welz et al., 2011). This observation points
to the existence of tissue-specific triggers
and modulators of RIPK3-dependent
necroptosis.
It is important to identify the crucial
factors in enteritis development. Enteritis
caused by FADDIEC-KO or caspase 8-
deficiency in IECs is characterized by
depletion of Paneth cells, which is thought
to contribute to the pathogenesis of
Crohn’s disease (CD). Indeed, necrotic
Paneth cells have been observed in the
gut crypts of CD patients (Gu¨nther et al.,
2011). IEC-specific gene ablation of
Nemo also results in colitis, although via
induction of apoptosis, and cannot be
rescued by additional Ripk3 deletion.
This suggests that a switch in cell death
mode can occur within the same tissue,
depending on the cellular conditions
(Welz et al., 2011). These observations
collectively emphasize the clinical impor-
tance of mouse models with artificial
ablation of the apoptosis machinery
because they bring deeper insight into
factors affecting pathological epithelial
inflammation in humans.
Could we apply the knowledge gath-
ered from the above-mentioned studiesto diseases other than CD? Patients with
homozygous inactivation of caspase-8
show not only characteristics of autoim-
mune lymphoproliferative syndrome
(ALPS) reflecting defective lymphocyte
apoptosis but also symptoms of eczema
and chronic diarrhea. Patients carrying
homozygous FADD mutations present
ALPS and have cardiovascular malforma-
tions (Bolze et al., 2010), as described in
casp-8/ and Fadd/mice (Kaiser et al.,
2011; Zhang et al., 2011). These observa-
tions suggest that targeting necroptosis
could be useful in these patients. Toxic
epidermal necrolysis (TEN), a rare, poten-
tially life-threatening, adverse drug reac-
tion in which large sheets of epidermis
blister from the skin, is believed to involve
keratinocyte apoptosis or necrosis as a
key mechanism of pathogenesis (Paquet
and Pie´rard, 2010). TEN has been associ-
ated with increased amounts of TNF,
TRAIL, and Fas, death receptors that
can induce necroptosis under appropriate
cellular conditions. Moreover, anti-TNF
therapy is widely used to treat severe
psoriasis. It would be worthwhile to inves-
tigate whether necroptosis plays a role in
the development of these diseases. The
studies of the Pasparakis and Becker
labs (Bonnet et al., 2011; Gu¨nther et al.,
2011; Welz et al., 2011) demonstrate the
need for careful re-evaluation of many
mouse disease models and human
pathologies for the occurrence of necrop-
tosis.We have probably often beenwrong
in assuming that apoptosis is manifested
in many pathological conditions on the
basis of the presence of TUNEL positivity,
which also detects necroptotic cells.
Finally, the new view of the causal rela-
tionship between necroptosis and several
inflammatory diseases strongly argues for
the development of diagnostic markersImmunity 35of necroptosis and efficient therapeutic
inhibitors targeting necroptosis.REFERENCES
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